A stapled peptide antagonist of MDM2 carried by polymeric micelles sensitizes glioblastoma to temozolomide treatment through p53 activation

详细信息    查看全文

• 作者：Xishan Chen^a ; ^b ; ^f ; Lingyu Tai^a ; ^c ; ^f ; Jie Gao^a ; ^f ; Jianchang Qian^a ; ^f ; Mingfei Zhang^a ; ^f ; Beibei Li^a ; ^f ; Cao Xie^a ; ^f ; Linwei Lu^d ; Wuyuan Lu^b ; ^{wlu@ihv.umaryland.edu" class="auth_mail" title="E-mail the corresponding author} ; Weiyue Lu^a ; ^e ; ^f ; ^g ; ^{wylu@shmu.edu.cn" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Stapled peptide ; p53 ; Micelle ; Glioma-targeting delivery ; Chemosensitization ; Temozolomide
• 刊名：Journal of Controlled Release
• 出版年：2015
• 出版时间：28 November 2015
• 年：2015
• 卷：218
• 期：Complete
• 页码：29-35
• 全文大小：922 K

文摘

Antagonizing MDM2 and MDMX to activate the tumor suppressor protein p53 is an attractive therapeutic paradigm for the treatment of glioblastoma multiforme (GBM). However, challenges remain with respect to the poor ability of p53 activators to efficiently cross the blood–brain barrier and/or blood–brain tumor barrier and to specifically target tumor cells. To circumvent these problems, we developed a cyclic RGD peptide-conjugated poly(ethylene glycol)-co-poly(lactic acid) polymeric micelle (RGD-M) that carried a stapled peptide antagonist of both MDM2 and MDMX (sPMI). The peptide-carrying micelle RGD-M/sPMI was prepared via film-hydration method with high encapsulation efficiency and loading capacity as well as ideal size distribution. Micelle encapsulation dramatically increased the solubility of sPMI, thus alleviating its serum sequestration. In vitro studies showed that RGD-M/sPMI efficiently inhibited the proliferation of glioma cells in the presence of serum by activating the p53 signaling pathway. Further, RGD-M/sPMI exerted potent tumor growth inhibitory activity against human glioblastoma in nude mouse xenograft models. Importantly, the combination of RGD-M/sPMI and temozolomide — a standard chemotherapy drug for GBM increased antitumor efficacy against glioblastoma in experimental animals. Our results validate a combination therapy using p53 activators with temozolomide as a more effective treatment for GBM.